Clinical trials: Type 2 Diabetes Mellitus (T2DM)
- Condition Type 2 Diabetes Mellitus (T2DM)
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
T2DM (Type 2 Diabetes Mellitus)
Food Effect and Multiple-Dose Study of Chiglitazar/Metformin Extended-Release Tablets
This trial includes two parts: a food effect (FE) study and a multiple-dose pharmacokinetic (PK) study. The FE study is a randomized, open-label, two-period, two-sequence crossover study designed to evaluate the effect of a…
- Trial name
- NCT07511010
- Testing
- Chiglitazar/Metformin extended-release tablets under fasting conditions, Chiglitazar/Metformin extended-release tablets after a high-fat meal, multiple-dose of Chiglitazar/Metformin extended-release tablets
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Chipscreen Biosciences, Ltd.
Healthy Participants
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
The purpose of this study is to measure the pharmacokinetics (PK-how the body processes the study drug) of elecoglipron in healthy participants when taken by mouth as different formulations.
- Trial name
- NCT07723833
- Testing
- Elecoglipron Reference Formulation Dose A, Elecoglipron Test formulation 1 Dose A, Elecoglipron Reference Formulation Dose B
- Where
- 2 sites in United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus (T2DM)
Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy® XR Extended Release Film Coated Tablets
Randomized, Single Oral Dose, Two-period, Two Sequence, Open-label, Crossover, Bioequivalence Study to Compare Empagliflozin-Linagliptin-Metformin XR Tablet 25mg/ 5mg/1000mg (25mg Empagliflozin /5mg Linagliptin /1000mgMetformin…
- Trial name
- NCT07213895
- Testing
- Empagliflozin/Linagliptin/Metformin HCL, Trijardy® XR Extended release film coated tablets
- Where
- Jordan
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Type 2 Diabetes Mellitus (T2DM)
To Compare and Evaluate the Oral Bioavailability of Empagliflozin + Linagliptin 10 mg/5 mg Filmcoated Tablets With That of Glyxambi 10 mg/ 5 mg Film-coated Tablets in Healthy, Adult, Human Subjects Under Fasting Conditions.
To compare and evaluate the oral bioavailability of Empagliflozin + Linagliptin 10 mg/5 mg film-coated tablets with that of Glyxambi 10 mg/ 5 mg film-coated tablets in healthy, adult, human subjects under fasting conditions.
- Trial name
- NCT07039890
- Testing
- Empagliflozin + Linagliptin filmcoated tablets, Glyxambi film-coated tablets
- Where
- India
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Type 2 Diabetes Mellitus
Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)
This study will assess the efficacy and safety of combination therapy of vildagliptin/metformin in patients with T2DM inadequately controlled with metformin 1,000 mg/day.
- Trial name
- NCT01196546
- Testing
- vildagliptin/metformin
- Where
- 8 sites in Thailand
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- Novartis
Diabetes Mellitus, Non-Insulin-Dependent, Hypertriglyceridemia
PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA
The primary objective of the study is to contrast the pharmacokinetic profiles of metformin and EPA delivered separately as co-administered products (metformin hydrochloride or Glucophage and icosapent ethyl or Vascepa) and…
- Trial name
- NCT02113163
- Testing
- Metformin Eicosapentaenoate, Metformin HCl and Vascepa
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Thetis Pharmaceuticals LLC
Healthy, Type 2 Diabetes Mellitus (T2DM)
A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)
The main purposes of this study are to determine: The safety of tirzepatide and any side effects that might be associated with it. How much tirzepatide gets into the bloodstream and how long it takes the body to get rid of it.
- Trial name
- NCT02759107
- Testing
- Tirzepatide, Dulaglutide
- Where
- 2 sites in United States, Singapore
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Bioequivalence, Fixed Dose Combination Tablets
A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects
This is a bioequivalence study to compare 2 fixed-dose combination tablets of dapagliflozin/metformin XR manufactured at 2 different plants in healthy subjects under fasting and fed conditions
- Conditions
- Bioequivalence, Fixed Dose Combination Tablets, Healthy Male and Female Subjects
- Trial name
- NCT02637037
- Testing
- dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon), dapagliflozin/metformin XR 5/500 mg reference drug (Humacao), dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon)
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus (T2DM)
Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM)
This study will assess safety, tolerability, and effect of LIK066 on blood glucose in healthy subjects and in patients with T2DM.
- Trial name
- NCT01407003
- Testing
- LIK066
- Where
- United States
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus (T2DM), Cardiovascular Diseases
Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCl 25 mg/5 mg/1000 mg Extended Release Tablet Versus Trijardy® XR 25 mg/5 mg/1000 mg Extended- Release Tablets
An open label, randomized, two-period, two treatment, two-sequence, crossover, balanced, single dose oral bioequivalence study to compare Empagliflozin/ Linagliptin/ Metformin HCl 25 mg/5 mg/1000 mg Extended Release Tablet versus…
- Trial name
- NCT07691203
- Testing
- Empagliflozin/Linagliptin/Metformin HCl Extended Release Tablet, Trijardy® XR Tablets
- Where
- India
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Type 2 Diabetes
IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics
This is a Phase I, first-in-human, randomised, double-blinded, placebo-and active-controlled study to assess the safety, tolerability, PK, PD, efficacy, and food-effect of IDG-16177 in healthy male subjects and patients with T2DM…
- Trial name
- NCT04982705
- Testing
- [Part 1.1] IDG-16177, [Part 2] Sitagliptin, [Part1.2] IDG-16177
- Where
- Germany
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- IlDong Pharmaceutical Co Ltd
T2DM (Type 2 Diabetes Mellitus)
The Drug-drug Interaction Study of AJU-A51R1 and AJU-A51R2
To evaluate a pharmacokinetic drug interaction between AJU-A51R1 and AJU-A51R2 in healthy male volunteers.
- Trial name
- NCT04970940
- Testing
- Treatment A, Treatment B, Treatment C
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AJU Pharm Co., Ltd.
Diabetes Mellitus, Type 2
A 2-Part Trial in Subjects With Type 2 Diabetes and in Healthy Subjects to Evaluate GSK1614235, a New Glucose Lowering Drug to Treat Type 2 Diabetes
The purpose of Part A of this study is to test whether repeated doses of the study drug (GSK1614235) are safe and well tolerated (i.e.
- Trial name
- SGA112534 (NCT00976261)
- Testing
- GSK1614235, Sitagliptin
- Where
- 9 sites in United States, France and 2 more
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes
Evaluation of a Nutritional Product for People With Type 2 Diabetes
The objective of this trial is to evaluate a nutritional product for people with Diabetes.
- Trial name
- NCT01850810
- Testing
- Experimental Study Product, Control Study Product
- Where
- 2 sites in United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Abbott Nutrition
Type 2 Diabetes Mellitus (T2DM), Renal Insuficiency
The Pharmacokinetics Study of Fotagliptin in Patients with Different Degrees of Renal Insufficiency
The trial was designed in a single dose, open, non-randomized, multi-dose parallel control group. The study of patients were mild and moderate renal insufficiency, and matched healthy subjects.
- Trial name
- RI (NCT06883656)
- Testing
- SAL067
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Type 2 Diabetes Mellitus (T2DM), Food Effect
Food Effect, Efficacy and Safety of MKP10241 in Healthy and Obese Adult Participants, With and Without Diabetes
The goal of this intervention study is to evaluate the safety, tolerability and pharmacokinetics (PK) and pharmacodynamics (PD) of multiple doses of MKP10241 in obese participants with and without T2DM in 3 parts.
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Food Effect, Safety and Tolerability, Obesity
- Trial name
- NCT07098663
- Testing
- MKP10241
- Where
- Australia
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Mankind Pharma Limited
Diabetes
A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose
A Study to Assess the Effect of CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose in Obese Male Subjects and Subjects with T2DM.
- Trial name
- NCT04973111
- Testing
- CT-868 as SC Injection, Active Comparator as SC Injection
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Carmot Therapeutics, Inc.
Type 2 Diabetes Mellitus (T2DM)
A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous UBT38006 Injection in Healthy Adult Males
This study is a single-center, randomized, double-blind, placebo- and active-controlled, parallel-group, single-ascending dose (SAD) design.
- Trial name
- NCT07630233
- Testing
- UBT38006, Insulin Degludec Injection, Insulin Icodec Injection
- Where
- China
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Non-alcoholic Steatohepatitis, Type 2 Diabetes Mellitus (T2DM)
A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy Subjects
The Sponsor is developing the test medicine, cotadutide, for the potential treatment of non-alcoholic steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM) with chronic kidney disease.
- Conditions
- Non-alcoholic Steatohepatitis, Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease
- Trial name
- NCT05294458
- Testing
- cotadutide solution for injection
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus (T2DM)
A Radiolabeled Mass Balance Study of [14C]-Ertugliflozin (PF04971729, MK-8835) In Healthy Male Participants (MK-8835-038)
This is single dose study of radiolabeled [14C]-ertugliflozin (PF04971729, MK-8835) in healthy male volunteers to study the absorption, distribution, metabolism and elimination of ertugliflozin.
- Trial name
- NCT01127308
- Testing
- Ertugliflozin
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC